CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.
June 17th 2024
Patients who received systemic therapy at the end of life did not have longer overall survival averages than those who did not receive therapy at end of life.
BCAN's First "Bladder Cancer Matters" Podcast is Now Available
February 2nd 2021In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.
BCAN Announces 2021 Bladder Cancer Research Innovation Award
January 26th 2021BCAN is pleased to announce two 2021 Bladder Cancer Research Innovation Awards to support the work of investigators with exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding of the management of bladder cancer.
BCAN Ranked as a Top Charity with a 4-Star Ranking for Seventh Consecutive Year
January 18th 2021The Bladder Cancer Advocacy Network’s (BCAN’s) strong financial health and commitment to accountability and transparency have earned it a seventh consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This award puts BCAN in the top seven percent of all charities.
BCAN Applauds Bill to Provide Long-Overdue Help to Veteran Bladder Cancer Patients
January 11th 2021The Bladder Cancer Advocacy Network (BCAN) is pleased that the U.S. Senate voted overwhelmingly to approve the National Defense Authorization Act (NDAA) which contains a critical provision that will help veterans who were exposed to Agent Orange and later developed bladder cancer.
Padcev, Keytruda Combination Proves Impactful for Patients with Metastatic Urothelial Cancer
February 20th 2020The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.